GlassScriptPhysician profile
Gretchen Hall
NPI 1942719000
$3,766.69
in general payments reported to CMS, 2019-2025
40 companies · $18.90 in 2025
The $18.90 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.52 · 2022: $1,101 · 2023: $1,439 · 2024: $1,134 · 2025: $18.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,592.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $345.29 | 2022-2024 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $284.27 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $263.05 | 2022-2024 | Keytruda, Lynparza |
| Lilly USA, LLC | $262.61 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $260.42 | 2021-2024 | Opdivo, Opdualag, Reblozyl |
| Janssen Biotech, INC. | $252.85 | 2021-2024 | Tecvayli, Talvey, Darzalex |
| Novartis Pharmaceuticals Corporation | $241.60 | 2022-2025 | |
| Pfizer INC. | $229.60 | 2022-2024 | |
| Celgene Corporation | $175.99 | 2022-2024 | Pomalyst, Reblozyl |
| Seagen INC. | $116.16 | 2023 | Adcetris, Tukysa, Padcev |
| Penumbra, INC. | $113.59 | 2023 | Indigo System |
| Eisai INC. | $98.39 | 2022-2024 | |
| Incyte Corporation | $93.90 | 2022-2024 | Jakafi |
| Genzyme Corporation | $86.24 | 2021-2024 | |
| Array Biopharma INC | $75.23 | 2022-2024 | Braftovi, Mektovi, Lorbrena |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $74.70 | 2022-2023 | Lynparza, Enhertu |
| Regeneron Healthcare Solutions, INC. | $74.17 | 2023-2024 | Libtayo |
| Abbvie INC. | $65.81 | 2024 | |
| Aveo Pharmaceuticals, INC. | $63.74 | 2022-2023 | Fotivda |
| Daiichi Sankyo INC. | $57.93 | 2024 | Enhertu |
| Pharmacosmos Therapeutics INC. | $55.34 | 2023-2024 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $52.26 | 2022-2024 | Somatuline Depot, Onivyde |
| Beigene USA, INC. | $44.44 | 2023-2024 | Brukinsa |
| Puma Biotechnology, INC. | $37.59 | 2021-2022 | |
| Csl Behring | $36.28 | 2022-2023 | Afstyla, Idelvion |
| Jazz Pharmaceuticals INC. | $35.05 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $29.47 | 2021-2023 | Xpovio |
| Stemline Therapeutics INC. | $24.20 | 2023 | Orserdu |
| Rigel Pharmaceuticals, INC. | $24.13 | 2023 | Rezlidhia, Tavalisse |
| Emd Serono, INC. | $21.85 | 2024 | |
| Heron Therapeutics, INC. | $21.32 | 2022 | |
| Amag Pharmaceuticals, INC. | $20.61 | 2022 | |
| Ge Healthcare | $20.07 | 2022 | |
| Sumitomo Pharma America, INC. | $18.59 | 2024 | Orgovyx |
| Genentech USA, INC. | $17.00 | 2022 | |
| Exelixis INC. | $16.15 | 2024 | Cabometyx |
| Astellas Pharma US INC | $14.82 | 2022 | |
| Taiho Oncology, INC. | $14.28 | 2024 | |
| Myovant Sciences INC. | $13.95 | 2022 | |
| Amgen INC. | $13.75 | 2023 | Lumakras |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gretchen Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.